Exenatide Once-weekly as a Treatment for Multiple System Atrophy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions

Multiple System Atrophy

Interventions

DRUG

Exenatide Pen Injector [Bydureon]

Exenatide is a treatment licensed for use in Type 2 diabetes.

Trial Locations (1)

Leonard Wolfson Experimental Neurology Centre, National Hospital of Neurology and Neurosurgery, UCLH NHS Foundation trust, London

All Listed Sponsors

lead

University College, London

OTHER

NCT04431713 - Exenatide Once-weekly as a Treatment for Multiple System Atrophy | Biotech Hunter | Biotech Hunter